HB 1165 would exempt certain menstrual hygiene products from North Carolina sales and use tax if they are certified as free of intentionally added PFAS. The bill defines “qualifying menstruation products” to include tampons, panty liners, menstrual cups, sanitary napkins, and similar products designed for menstrual hygiene, but only if they meet the PFAS-free certification standard established by the Department of Commerce. It also directs the Department of Commerce to create and administer a certification program, adopt testing and product standards, accept applications from manufacturers, and issue certifications valid for five years.
The bill creates an interim pathway for certification before permanent rules are adopted: products already certified by nationally recognized independent testing laboratories, such as Intertek or NSF, would be deemed to satisfy the state standard. It also requires manufacturers to notify the department of material changes, allows decertification for noncompliance or misrepresentation, and makes knowingly false statements in an application a Class 2 misdemeanor. In addition, the bill instructs the Secretary of Revenue to seek an amendment to the Streamlined Sales and Use Tax Agreement so the tax exemption can be implemented consistently with that agreement, and it appropriates $100,000 to the Department of Revenue for that effort.
If enacted, the bill would amend North Carolina’s sales tax statutes to add a new exemption for qualifying menstruation products and would add a new certification program in Chapter 143B governing PFAS-free menstrual products. It would affect consumers purchasing menstrual hygiene products, manufacturers seeking certification, the Department of Commerce as the certifying agency, and the Department of Revenue in relation to sales tax administration and the interstate tax agreement process. The bill also creates a new compliance and enforcement framework around PFAS content in these products.
The available legislative history shows no recorded votes or committee debate, so there is no documented floor or committee sentiment in the materials provided. Based on the bill’s structure, the measure appears to combine consumer tax relief with public-health and environmental concerns about PFAS exposure, suggesting a policy rationale likely to appeal to supporters of menstrual equity and chemical safety. Because the bill was only referred to the House Rules Committee and has no recorded discussion here, the level of support or opposition cannot be determined from the provided record.
Potential points of contention include the cost and administrative burden of creating and maintaining the certification program, the need to conform the exemption to the Streamlined Sales and Use Tax Agreement, and the reliance on testing standards and third-party laboratory certifications. Manufacturers may also be affected by documentation, renewal, and decertification requirements, while tax administrators may need to adjust systems to recognize a new exempt product category.
The bill would amend North Carolina’s sales tax definitions and exemptions to exclude qualifying PFAS-free menstruation products from state sales and use tax, while also creating a new certification program in Chapter 143B for the Department of Commerce to verify that such products contain no intentionally added PFAS. It would add compliance, renewal, decertification, and misdemeanor penalty provisions for false statements, and it would require the Department of Revenue to pursue a Streamlined Sales and Use Tax Agreement amendment before the tax exemption can take effect. The bill also appropriates $100,000 to the Department of Revenue for implementation-related work.
No committee transcript or vote record is provided, so there is no direct evidence of support or opposition from legislators in the available materials. The bill’s design suggests a generally favorable policy posture toward menstrual product affordability and PFAS reduction, but the absence of recorded debate means sentiment must be inferred rather than documented. The referral status indicates the bill was still in the early committee process at the time of the last action.
The main likely points of contention are the fiscal impact of the tax exemption and the administrative complexity of certifying products as PFAS-free. Another issue is the requirement to coordinate with the Streamlined Sales and Use Tax Agreement, which may delay implementation or require interstate approval. Manufacturers may also object to testing, reporting, and renewal obligations, while regulators may need to balance consumer protection goals against the burden of rulemaking and enforcement. No specific objections or supporters are identified in the provided record.